Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.

BACKGROUND AND OBJECTIVE Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disease of the hemopoietic stem cell (HSC) characterized by intravascular hemolysis and increased risk of venous thrombosis. There are different therapeutic approaches for PNH which do not cure the disease, but can decrease its complications. Allogeneic bone marrow transplantation (BMT) may cure PNH. We reports here our experience of seven PNH patients who underwent allogeneic BMT. DESIGN AND METHODS Between January 1991 and January 1999 seven patients with PNH, aged 23 to 37, were transplanted with unmanipulated bone marrow from HLA identical siblings. Median time from diagnosis to BMT was 2.5 years (range: 1-16). All patients were transfusion-dependent and had received various treatments before BMT: steroids, vitamins, cyclosporin A (CyA), growth factors. One patient had also been treated with anti-thymocyte globulin. One patient was HbsAg positive and one anti-HCV positive. At the time of BMT the median value of hemoglobin (Hb) was 9 g/dL (range 6.5-11), white blood cells 5&10(9)/L (range: 2.9-7.7), platelets 97&10(9)/L (range: 31-355), LDH: 2726 U/L. The conditioning regimen was cyclophosphamide (160 mg/kg) and busulfan (10-14 mg/kg), followed by unmanipulated bone marrow (median of 5&10(8) cells/kg) and CyA (+MTX in two patients) for prophylaxis of graft-versus-host disease (GvHD). RESULTS All seven patients are alive, full chimeras, with complete hematologic recovery and no evidence of PNH, at a median follow up of 51 months post-BMT (6-103). Time to achieve a granulocyte count of 0.5&10(9)/L, platelets 30&10(9)/L and Hb 10 g/dL was respectively 16, 19 and 22 days. Acute GvHD was limited or mild in six patients, and severe in one. Chronic GvHD was extensive in two patients. INTERPRETATION AND CONCLUSIONS This study confirms that HLA identical sibling BMT is an effective therapeutic option for PNH, also in the hemolytic phase of the disease: it also suggests that HBV and HCV infections are not an absolute contraindication.

[1]  V. Rosti.  The molecular basis of paroxysmal nocturnal hemoglobinuria. , 2000, Haematologica.

[2]  H. Esperou,et al.  Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[3]  L Luzzatto,et al.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Luzzatto,et al.  Bone marrow transplants for paroxysmal nocturnal haemoglobinuria , 1999, British journal of haematology.

[5]  C. Packman.  Pathogenesis and management of paroxysmal nocturnal haemoglobinuria. , 1998, Blood reviews.

[6]  W. Rosse,et al.  The natural history of paroxysmal nocturnal hemoglobinuria. , 1997, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[7]  A. Ganser,et al.  G-CSF and cyclosporin induce an increase of normal cells in hypoplastic paroxysmal nocturnal hemoglobinuria , 1997, Annals of Hematology.

[8]  Lucio Luzzatto,et al.  Somatic Mutations in Paroxysmal Nocturnal Hemoglobinuria: A Blessing in Disguise? , 1997, Cell.

[9]  R. Paquette,et al.  Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria , 1997, British journal of haematology.

[10]  A. Locasciulli.  Hepatitis viruses infections in bone marrow transplantation. , 1996, Bone marrow transplantation.

[11]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[12]  C. Arnoulet,et al.  Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration , 1996, British journal of haematology.

[13]  H. Schrezenmeier,et al.  [Paroxysmal nocturnal hemoglobinuria. Clinical experiences with 40 patients at one center over 25 years]. , 2008, Deutsche medizinische Wochenschrift.

[14]  R. Ware,et al.  The molecular basis of paroxysmal nocturnal hemoglobinuria. , 1995, Blood.

[15]  F. Sigaux,et al.  Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. , 1995, Blood.

[16]  E. Vellenga,et al.  The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria , 1995, British journal of haematology.

[17]  H. Heimpel,et al.  A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. , 1995, Experimental hematology.

[18]  R. Storb,et al.  Marrow transplantation for paroxysmal nocturnal hemoglobinuria , 1992, American journal of hematology.

[19]  T. Asai,et al.  Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. , 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[20]  W. Rosse.  Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome. , 1989, Blood reviews.

[21]  H. Gerhartz,et al.  Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemoglobinuria. , 1989, Bone marrow transplantation.

[22]  S. Orkin,et al.  Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. , 1985, Blood.

[23]  H. Deeg,et al.  Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. , 1984, Annals of internal medicine.

[24]  Dacie Jv,et al.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. , 1972, Series haematologica.

[25]  S. Lewis,et al.  Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease. , 1972, Series haematologica.